The ACR issued a 2025 guideline for the treatment of SLE that addressed treatment and management of specific organ system ...

A new groundbreaking study has recently identified the link between the long-standing mystery in autoimmune disease: ...

Topline data were announced from a phase 3 trial evaluating obinutuzumab in adults with systemic lupus erythematosus on standard therapy.

A notable proportion of patients with systemic lupus erythematosus report taking five or more medications simultaneously, ...

A new study highlights potential therapies to decrease cardiovascular risk in people with systemic lupus erythematosus (SLE) and identifies biomarkers that may indicate a heightened risk.

LLDAS response rate observed in patients with SLE who received Descartes-08 in Phase 2 open-label trial reaching Month 3 follow-up (n=3) ...

Despite their routine use for managing systemic lupus erythematosus, data supporting the effect of antimalarials in protecting against lupus nephritis are limited.

Please provide your email address to receive an email when new articles are posted on . SLE-DAS remission and low disease activity discriminated between patients taking active drug vs. placebo. Both ...

In a recent study published in PLOS Genetics, researchers identified a genetic association signal, via genome-wide association (GWA) studies, between severe coronavirus disease 2019 (COVID-19) with ...

Like in other chronic inflammatory disorders, achieving disease activity control in SLE requires the application of the treat-to-target strategy. This approach requires setting clear treatment targets ...